Find information on thousands of medical conditions and prescription drugs.

Zonisamide

Zonisamide (brand name Zonegran®) is a sulfonamide anticonvulsant approved for use as an adjunctive therapy in adults with partial-onset seizures. It was discovered by researchers at Dainippon Sumitomo Pharma (大日本住友製薬: Dainippon Sumitomo Seiyaku (formerly Dainippon Pharmaceutical (大日本製薬: Dainippon Seiyaku)), who launched it in 1989 as Excegran® in Japan. It was marketed by Élan in the United States starting in 2000 as Zonegran®, before Élan transferred their interests in zonisamide to Eisai (エーザイ) in 2004. more...

Home
Diseases
Medicines
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Zafirlukast
Zagam
Zalcitabine
Zaleplon
Zanaflex
Zanamivir
Zantac
Zarontin
Zelnorm
Zerit
Zestoretic
Zestril
Zetia
Zevalin
Ziagen
Zidovudine
Zileuton
Ziprasidone
Zithromax
Zocor
Zofran
Zoladex
Zoledronic acid
Zolmitriptan
Zoloft
Zolpidem
Zometa
Zomig
Zonegran
Zonisamide
Zopiclone
Zosyn
Zovia
Zovirax
Zyban
Zymar
Zyprexa
Zyrtec
Zyvox

Eisai also markets Zonegran® in Asia (China, Taiwan, and fourteen others) and Europe (starting in Germany and the United Kingdom).

Uses

Approved

Zonisamide is approved in the United States, United Kingdom, and Japan for adjunctive treatment of partial seizures in adults.

Unapproved/Off-Label/Investigational

An open trial on zonisamide in seven Parkinson's disease patients had positive results, according to this 2001 report. Since then, it has been reported to treat the resting tremor that other therapies may leave behind. By early November of 2005, Dainippon Sumitomo had filed a NDA for the use of zonisamide in Parkinson's disease; it is to be marketed as Tremode®.

Metabolism

Zonisamide is metabolized mostly by the CYP3A4 isoenzyme, but also CYP3A7 and CYP3A5, to 2-(sulphamoylacetyl)-phenol via reductive cleavage of the 1,2-benzisoxazole ring.

Mechanism of Action

The exact mechanism of action is not known for zonisamide. According to Leppik, while zonisamide may be a carbonic anhydrase inhibitor like acetazolamide, this is not one of the primary mechanisms of action, which might be blocking repetitive firing of voltage-gated sodium channels and reduction of T-type calcium channel currents, or by binding allosterically to GABA receptor like the benzodiazepines and muscimol, or increasing the levels of the glutamate transport protein in the brain while decreasing the amount of GABA transport protein, in other words, inhibiting the uptake of the inhibitory neurotransmitter GABA while enhancing the uptake of the excitatory neurotransmitter glutamate.

Read more at Wikipedia.org


[List your site here Free!]


Zonisamide may benefit chronic pain patients. (Anticonvulsant for Pain). : An article from: Clinical Psychiatry News $5.95 Effectiveness of zonisamide increases with time. (Seizure Frequency Decreased). : An article from: Clinical Psychiatry News $5.95
Zonisamide effectiveness increases with time. (Epilepsy Therapy). : An article from: Internal Medicine News $5.95

Zonisamide effective for weight loss in women - Patient Oriented Evidence That Matters: practice recommendations from key studies
Gadde KM, Franciscy DM, Wagner HR, Krishnan KRR. Zonisamide for weight loss in obese adults. A randomized controlled trial. JAMA 2003; 289:1820-1825.
Zonisamide for weight loss - Assessment and Treatment of Obesity - antiepileptic agents for obesity - Author Abstract
There is good evidence that pharmacotherapy can enhance weight loss when combined with interventions aimed at changing lifestyle, although pharmacological ...
Zonisamide May Help Patients with Medication-Resistant Epilepsy
(American Academy of Neurology) Zonisamide (Zonegran), a drug under investigation in the United States, appears to be effective in the treatment of patients ...
Barr Receives Approval for Zonisamide Capsules, 25 mg, 50 mg & 100 mg
WOODCLIFF LAKE, N.J., Dec. 23 /PRNewswire-FirstCall/ -- Barr Pharmaceuticals, Inc. today announced that it's subsidiary, Barr Laboratories, Inc., has received final approval from the U.S. Food an
Apotex Receives Final Approval for Zonisamide Capsules
WESTON, Fla. -- Apotex Corp. today announced that it has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated ...
Mylan Announces Final FDA Approval for Zonisamide Capsules
PITTSBURGH, Dec. 23 /PRNewswire-FirstCall/ -- Mylan Laboratories Inc. today announced that Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA)
"Pacemaker for the brain" may help stop seizures
Dear Dr. SerVaas, My 20-year-old grandson developed epilepsy, having his first grand mal 3/23/01 when he was 17. Three years previous to that, there ...
Mitigating Cognitive Side Effects Associated with Topiramate
This column offers a question-and-answer forum to help nurses maintain their knowledge of advances in prescribing and psychopharmacology, and implications ...

Home Contact Resources Exchange Links ebay